These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 2164441)

  • 1. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
    Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z
    Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical assessment of 90Y-labeled monoclonal antibody CO17-1A, a potential agent for radioimmunotherapy of colorectal carcinoma.
    Washburn LC; Lee YC; Sun TT; Byrd B; Crook JE; Stabin MG; Steplewski Z
    Int J Rad Appl Instrum B; 1988; 15(6):707-11. PubMed ID: 3251904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of five bifunctional chelate techniques for 90Y-labeled monoclonal antibody CO17-1A.
    Washburn LC; Sun TT; Lee YC; Byrd BL; Holloway EC; Crook JE; Stubbs JB; Stabin MG; Brechbiel MW; Gansow OA
    Int J Rad Appl Instrum B; 1991; 18(3):313-21. PubMed ID: 2071444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of bone marrow transplantation in 90Y antibody therapy of colon cancer xenografts in nude mice.
    Morton BA; Beatty BG; Mison AP; Wanek PM; Beatty JD
    Cancer Res; 1990 Feb; 50(3 Suppl):1008s-1010s. PubMed ID: 2297712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
    Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
    Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.
    Roselli M; Schlom J; Gansow OA; Raubitschek A; Mirzadeh S; Brechbiel MW; Colcher D
    J Nucl Med; 1989 May; 30(5):672-82. PubMed ID: 2785585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
    Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
    Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
    Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
    Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
    Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
    J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
    Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
    Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
    Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.
    Riva P; Franceschi G; Frattarelli M; Lazzari S; Riva N; Giuliani G; Casi M; Sarti G; Guiducci G; Giorgetti G; Gentile R; Santimaria M; Jermann E; Maeke HR
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
    J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.